A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules
Table 1
Baseline characteristics of HCC patients involved in this research.
Characteristics
TCGA-LIHC dataset (N = 365)
ICGC-LINC-JP dataset (N = 231)
Age
≤60
173 (47.4%)
49 (21.2%)
>60
192 (52.6%)
182 (78.8%)
Gender
Male
246 (67.4%)
170 (73.6%)
Female
119 (32.6%)
61 (26.4%)
Grade
G1
55 (15.1%)
NA
G2
175 (47.9%)
NA
G3
118 (32.3%)
NA
G4
12 (3.3%)
NA
Unknown
5 (1.4%)
NA
Stage
Stage I
170 (46.6%)
36 (15.6%)
Stage II
84 (23.0%)
105 (45.5%)
Stage III
83 (22.7%)
71 (30.7%)
Stage IV
4 (1.1%)
19 (8.2%)
Unknown
24 (6.6%)
0 (0.0%)
T stage
T1-2
271 (74.2%)
NA
T3-4
91 (24.9%)
NA
Unknown
3 (0.8%)
NA
N stage
N0
248 (67.9%)
NA
N1
4 (1.1%)
NA
Unknown
113 (31.0%)
NA
M stage
M0
263 (72.1%)
NA
M1
3 (0.8%)
NA
Unknown
99 (27.1%)
NA
Survival status
Alive
235 (64.4%)
189 (81.8%)
Deceased
130 (35.6%)
42 (18.2%)
Chronic liver disease/cirrhosis
NA
NA
HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; LIHC, liver hepatocellular carcinoma; ICGC, International Cancer Genome Consortium.
